Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders using a brain-targeting chemistry platform. Its lead program, ABX-002, is an oral, selective thyroid hormone beta receptor (TRβ) agonist that showed CNS target engagement and favorable tolerability in Phase 1. The company plans to initiate two Phase 2 trials of ABX-002 in the second half of 2024 as adjunctive treatment for major depressive disorder and bipolar depression. Autobahn will also advance ABX-101, a highly CNS-penetrant oral S1P receptor modulator, into Phase 1 clinical testing to target neuroimmunologic and neuroinflammatory disorders. Preclinical data for ABX-101 demonstrated exceptional CNS exposure and robust centrally mediated effects in animal models. The company is based in San Diego and intends to use recent financing to rapidly progress these programs through clinical development. Autobahn Therapeutics leverages a proprietary brain‑targeting chemistry platform to develop precision CNS therapeutics. Its lead program, ABX‑002, is a potent, selective thyroid receptor‑beta (TRβ) agonist designed to augment antidepressant effects and enhance serotonin activity in treatment‑resistant depression (TRD) patients. The company plans to initiate a Phase 1 single‑ and multiple‑ascending dose trial of ABX‑002 in healthy volunteers in the second half of 2022. Autobahn has assembled a TRD‑focused scientific advisory board with leaders from neurology, psychiatry and drug development to guide its program. Beyond TRD, Autobahn will evaluate ABX‑002 for additional indications including remyelination and multiple sclerosis and will use its chemistry platform to identify further programs. The company is based in San Diego. Autobahn Therapeutics is focused on developing next-generation regenerative medicines for CNS disorders by leveraging a brain-targeting chemistry platform and validated thyroid hormone biology. Its lead program, ABX-002, is a thyroid hormone receptor beta agonist being developed for multiple sclerosis and adrenomyeloneuropathy. The company develops small-molecule thyromimetics designed to stimulate remyelination and selectively maximize exposure in the brain. Autobahn intends to use biomarker-driven development to establish on-target activity and early proof-of-mechanism. Leadership includes experienced executives and scientific founders such as Kevin Finney (CEO) and Thomas Scanlan (co-founder and senior advisor). The company is advancing a broader portfolio of CNS programs built on the same platform and has just completed a significant Series B financing to fund near-term development.

Total raised

$209M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2024